Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2

Journal of Cellular Biochemistry

Volumn 104, Issue 2, 2008, Pages 680-691

  Nagai, Tadashi ^a   Kikuchi, Satoru ^a   Ohmine, Ken ^a   Miyoshi, Takuji ^a   Nakamura, Makiko ^a   Kondo, Takahito ^b   Furuyama, Kazumichi ^c   Komatsu, Norio ^d   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Anthracyclin; Drug resistance; Heme; Imatinib; KCL22; Nrf2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AMINOLEVULINIC ACID; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLUTAMATE CYSTEINE LIGASE; HEME OXYGENASE 1; HEMIN; HYDROXYUREA; IDARUBICIN; IMATINIB; LY 294001; MITOXANTRONE; RAPAMYCIN; SUCCINYLACETONE; TRANSCRIPTION FACTOR NRF2;

APOPTOSIS; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HEME SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SENSITIVITY ANALYSIS;

ANTHRACYCLINES; CELL LINE, TUMOR; DRUG INTERACTIONS; DRUG RESISTANCE; HEMIN; HUMANS; LEUKEMIA; NF-E2-RELATED FACTOR 2; PIPERAZINES; PYRIMIDINES; UP-REGULATION;

EID: 43449139414     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21659     Document Type: Article

References (34)

1. Bloom J, Pagano M. 2003. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 13:41-47.
2. Bonovolias ID, Manley PW, Tsiftsoglou AS. 2006. Hemin confers resistance to imatinib (Glivec)-induced cell death but enhances nilotinib (AMN107) cytotoxicity in human K-562 CML leukemia cells. Blood 108:275b.
3. Brady HJ. 2003. Apoptosis and leukaemia. Br J Haematol 123:577-585.
4. Collins SJ, Gallo RC, Gallagher RE. 1977. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270:347-349.
5. Deininger M, Buchdunger E, Druker BJ. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653.
6. Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK. 2005. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H: Quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J Biol Chem 280:16891-16900.
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. 2001. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
8. Estrela JM, Ortega A, Obrador E. 2006. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43:143-181.
9. Ferris CD, Jaffrey SR, Sawa A, Takahashi M, Brady SD, Barrow RK, Tysoe SA, Wolosker H, Baranano DE, Dore S, Poss KD, Snyder SH. 1999. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1:152-157.
10. Granick JL, Sassa S. 1978. Hemin control of heme biosynthesis in mouse Friend virus-transformed erythroleukemia cells in culture. J Biol Chem 253:5402-5406.
11. Iida T, Mori E, Mori K, Goto S, Urata Y, Oka M, Kohno S, Kondo T. 1999. Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int J Cancer 82:405-411.
12. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, Yamamoto M. 2000. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275:16023-16029.
13. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322.
14. Kirschner KM, Baltensperger K. 2003. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells. Mol Cancer Res 1:970-980.
15. Komatsu N, Watanabe T, Uchida M, Mori M, Kirito K, Kikuchi S, Liu Q, Tauchi T, Miyazawa K, Endo H, Nagai T, Ozawa K. 2003. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem 278:6411-6419.
16. Kubonishi I, Miyoshi I. 1983. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1:105-117.
17. Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, Marculescu R, Printz D, Fritsch G, Wagner O, Selzer E, Sperr WR, Valent P, Sillaber C. 2004. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res 64:3148-3154.
18. Miyoshi T, Nagai T, Ohmine K, Nakamura M, Kano Y, Muroi K, Komatsu N, Ozawa K. 2005. Relative importance of apoptosis and cell cycle blockage in synergistic effect of combined R115777 and imatinib treatment differs among BCR/ABL-positive cell lines. Biochem Pharmacol 69:1585-1594.
19. Moi P, Chan K, Asunis I, Cao A, Kan YW. 1994. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91:9926-9930.
20. Nagai T, Harigae H, Furuyama K, Munakata H, Hayashi N, Endo K, Sassa S, Yamamoto M. 1997. 5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line. J Biochem 121:487-495.
21. Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K. 2003. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells 21:315-321.
22. Oyake T, Itoh K, Motohashi H, Hayashi N, Hoshino H, Nishizawa M, Yamamoto M, Igarashi K. 1996. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol 16:6083-6095.
23. Papadopoulou LC, Tsiftsoglou AS. 1996. Related Articles, Links Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). Biochem Pharmacol 52:713-722.
24. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F. 2006. Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials. Blood 108:1478-1484.
25. Sassa S, Kappas A. 1983. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 71:625-634.
26. Sassa S, Nagai T. 1996. The role of heme in gene expression. Int J Hematol 63:167-178.
27. Sassa S. 1976. Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells. J Exp Med 143:305-315.
28. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539.
29. Shibahara S. 2003. The heme oxygenase dilemma in cellular homeostasis: New insights for the feedback regulation of heme catabolism. Tohoku J Exp Med 200:167-186.
30. Sundstrom C, Nilsson K. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17:565-577.
31. Tarumoto T, Nagai T, Ohmine K, Miyoshi T, Nakamura M, Kondo T, Mitsugi K, Nakano S, Muroi K, Komatsu N, Ozawa K. 2004. Ascorbic acid restores the sensitivity to imatinib through suppression of Nrf2-dependent gene expression in a imatinib-resistant cell line, KCL22/SR. Exp Hematol 32:375-381.
32. Tsiftsoglou AS, Wong W, Wheeler C, Steinberg HN, Robinson SH. 1986. Prevention of anthracycline-induced cytotoxicity in hemopoietic cells by hemin. Cancer Res 46:3436-3440.
33. Venugopal R, Jaiswal AK. 1996. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H: Quinone oxidoreductase 1 gene. Proc Natl Acad Sci U S A 93:14960-14965.
34. Venugopal R, Jaiswal AK. 1998. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17:3145-3156.